LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Sharma, Rohini ^a   Hamilton, Anne ^b   Beith, Jane ^b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; METHOTREXATE; TAMOXIFEN; TRIPTORELIN; VINCRISTINE;

ADJUVANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MULTIPLE CYCLE TREATMENT; PREMENOPAUSE; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

EID: 55049119525     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004562.pub3     Document Type: Review

References (56)

1. ABCSG 5 {published data only} Gnant M, Greil R, Kubista E, et al.The impact of treatment-induced amenorrhea on survival of premenopausal patients with endocrine-responsive breast cancer: 10-year results of ABCSG-05 (CMF vs. goserelin+tamoxifen). Breast Cancer Research and Treatment 2006;100 (suppl 1):S10-1 (abstract 17).
2. * Jakesz R, Hausmaninger H, Kubista E, et al.Randomised adjuvant trial of tamoxifen and goserelin versus cyclophosphamide,methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in pre-menopausal patients with hormone responsive breast cancer Austrian Breast and Colorectal Cancer Study Group trial 5. Journal of Clinical Oncology 2002;20:4621-7.
3. ECOG 5188 INT-0101 {published data only} Davidson N, ONeil A, Vukov A, et al.Effect of chemohormonal therapy in pre-menopausal, node (+), receptor (+) breast cancer: an eastern cooperative oncology group phase III Intergroup trial (E5188, INT-0101). Proceedings of the American Society of Clinical Oncology. 2003:5 (abstract 15).
4. FASG 06 {published data only} Roche H, Kerbrat P, Bonneterre J, et al.Complete hormonal blockade versus chemotherapy in pre-menopausal early-stage breast cancer patients (pts) with positive hormone-receptor (HR+) and 13 node-positive (N+) tumor: results of the FASG06 trial. Proceedings of the American Society of Clinical Oncology. 2000:72a (abstract 279).
5. GABG IV-A-93 {published data only} * von Minckwitz G, Graf E, Geberth M, et al.Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal women. The GABG trial IV-A-93 Trial. Proceedings of the American Society of Clinical Oncology. 2004:11s (abstract 534).
6. von Minckwitz G, von de Assesn A, Conrad B, et al.Medical ovarian ablation versus polychemotherapy in premenopausal women with node-negative, receptor positive breast cancer. The ongoing trial 'A-93' of the German Adjuvant Greast Cancer Group (GABG). Proceedings of the American Society of Clinical Oncology. 1999:(abstract 395).
7. GABG IV-B-93 {published data only} Kaufmann M, Graf E, Jonat W, et al.Goserelin versus control after adjuvant, risk adapted chemotherapy in premenopausal women with breast cancer. GABG trial IV-B-93. Proceedings of the American Society of Clinical Oncology. 2004:24s (abstract 588).
8. GROCTA 02 {published data only} Boccardo F, Rubagotti A, Amoroso D, et al.CMF versus tamoxifen (TAM) plus goserelin (GOS) as adjuvant treatment of ER positive (ER+) pre-perimenopausal breast cancer (CA) patients (PTS). Preliminary results of the GROCTA 02 study. Proceedings of the American Society of Clinical Oncology. 1998:(abstract 382).
9. Boccardo F, Rubagotti A, Amoroso D, et al.CMF versus tamoxifen plus goserelin as adjuvant treatment of ER-positive pre-perimenopausal breast cancer patients: preliminary results of an ongoing Italian Breast Cancer Adjuvant Study Group (GROCTA) trial. In: Salmon SE editor(s). Adjuvant Therapy of Cancer VIII. Philadelphia: Lippincott-Raven Publishers, 1997:101-8.
10. * Boccardo F, Rubagotti A, Amoroso D, et al.Cyclophosphamide, methotrexate and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of oestrogen receptor-positive pre-/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomised trial. Journal of Clinical Oncology 2000;18:2718-27.
11. IBCSG VIII {published data only} Bernhard J, Zahrieh D, Castiglione-Gertsch M, et al.Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients: the International Breast Cancer Study Group Trial VIII. Journal of Clinical Oncology 2007;25:263-70.
12. Castiglione-Gertsch M, ONeill A, Gelber RD, et al.Is the addition of adjuvant chemotherapy always necessary in node negative (N-) pre/perimenopausal breast cancer patients (pts) who receive goserelin?: first results of IBCSG trial VIII. Proceedings of the American Society of Clinical Oncology. 2001:38a (abstract 149).
13. * International Breast Cancer Study Group. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. Journal of the National Cancer Institute 2003;95:1833-46.
14. MAM 01 GOCSI {published data only} Bianco AR, Costanzo R, Di Lorenzo G, et al.The MAM-1 GOCSI trial: a randomised trial with factorial design of chemo-endocrine adjuvant treatment in node positive (N+) early breast cancer (ebc). Proceedings of the American Society of Clinical Oncology. 2001:27a (abstract 104).
15. * De Placido S, De Laurentiis M, De Lena M, et al.A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. British Journal of Cancer 2005;92:467-74.
16. Pretoria {published data only} Falkson CI, Falkson HC, Falkson G. The effect of chemotherapy with or without GnHRA on serum hormone levels in premenopausal women with breast cancer. Proceedings of the American Society of Clinical Oncology. 1990:(abstract 90).
17. * Falkson CI, Jooste R, Falkson HC, et al.Cyclophosphamide, methotrexate and fluorouracil (CMF) plus or minus depo-buserelin in pre-menopausal women with lymph node positive breast cancer. Proceedings of the American Society of Clinical Oncology. 2001:7b (abstract 1777).
18. Soreide 2002 {published data only} * Soreide JA, Varhaug JE, Fjosne HE, et al.Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomised national multicenter study. European Journal of Surgical Oncology 2002;28:505-10.
19. TABLE {published data only} * Schmid P, Untch M, Wallwiener D, et al.Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast Cancer Study with Leuprorelin acetate). Anticancer Research 2002;22:2325-32.
20. Untch M, Kahlert S, Kosse V, et al.LHRH-analogue therapy with leuprorelin-acetate three-month depot offers similar efficacy to conventional adjuvant CMF chemotherapy in receptor positive, node positive breast cancer patients. San Antonio Breast Cancer Symposium. 2003:(abstract 40).
21. ZBCSG Trial B {published data only} * Mitsuyama S, Nomura Y, Ohno S, et al.Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan - Zoladex Breast Cancer Study Group Trial-B [Japanese]. Japanese Journal of Cancer Chemotherapy 2005;32:2071-7.
22. ZEBRA {published data only} de Haes H, Olschewski M, Kaufman M, et al.Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. Journal of Clinical Oncology 2003;21:4510-6.
23. * Jonat W, Kaufman M, Sauerbrei W, et al.Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in pre-menopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association study. Journal of Clinical Oncology 2002;20:4628-35.
24. ZIPP {published data only} * Baum M, Hackshaw A, Houghton J, et al.Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. European Journal of Cancer 2006;42:895-904.
25. Baum M, Houghton J, Sawyer W, et al.Management of premenopausal women with early breast cancer: is there a role for goserelin?. Proceedings of the American Society of Clinical Oncology. 2001:38a (abstract 103).
26. Nystedt M, Berglund G, Bolund C, et al.Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomised study. Journal of Clinical Oncology 2003;21:1836-44.
27. Arriagada 2005 {published data only} Arriagada R, Le M, Spielmann M, et al.Randomized trial of adjuvant ovarian suppression in 926 pre-menopausal patients with early breast cancer treated with adjuvant chemotherapy. Annals of Oncology 2005;16:389-96.
28. PERCHE {published data only} IBCSG PERCHE. Ongoing study Starting date of trial not provided. Contact author for more information.
29. SOFT {published data only} IBCSG SOFT. Ongoing study Starting date of trial not provided. Contact author for more information.
30. UKCCR {published data only} UKCCR. Ongoing study Starting date of trial not provided. Contact author for more information.
31. Baum 2006 Baum M, Hackshaw A, Houghton J, et al.Adjuvant goserelin in premenopausal patients with early breast cancer: Results from the ZIPP study. European Journal of Cancer 2006;42:895-904.
32. Bernhard 2007 Bernhard J, Zahrieh D, Castiglione-Gertsch M, et al.Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients: the International Breast Cancer Study Group Trial VIII. Journal of Clinical Oncology 2007;25:263-70.
33. Bines 1996 Bines J, Oleske DM, Cobleigh MA. Ovarian function in pre menopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 1998;14:1718-29.
34. Cuzick 2006 Cuzick J, on behalf of the LHRH-Agonist Overview Group. The impact of LHRH agonists on breast cancer recurrence and mortality: an overview of the randomised trials. Breast Cancer Research and Treatment 2006;100(Suppl 1):s10 (abstract 15).
35. Davidson 2003 Davidson NE, O'Neill A, Vukov A, Osborne CK, Martino S, White D, et al.Chemohormonal therapy in premenopausal node-positive, receptor positive breast cancer: An Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101). Proceedings of the American Society of Clinical Oncology. 2003.
36. de Haes 2003 de Haes H, Olschewski M, Kaufman M, et al.Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group. Journal of Clinical Oncology 2003;21:4510-6.
37. EBCTCG 1996 Early Breast Cancer Trialists' Collaborative Group. Ovarian oblation in early breast cancer: Overview of the randomised trials. Lancet 1998;348:1189-96.
38. EBCTCG 2003 Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation for Early Breast Cancer (Cochrane Review). Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD000485]
39. EBCTCG 2005 Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
40. Ejlertsen 1999 Ejlertsen B, Dombernowsky P, Mouridsen HT, Kamby C, Kjaer M, Pose C, et al.Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients. Proceedings of the American Society of Clinical Oncology. 1999; Vol. 18:66a.
41. Ferlay 2001 Ferlay JB, Pisani P, Parkin DM. Cancer Incidence, Mortality and Prevalence worldwide. Cancer Base No 5. IARC Press, 2001.
42. Furr 1989 Furr BJA. Pharmacology of the Luteinising Hormone Releasing Hormone (LHRH) analog "Zoladex". Hormonal Research 1989;32(Suppl 1):86-92.
43. Gelber 1996 Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, et al.Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality adjusted survival. Lancet 1996;347:1066-71.
44. Higgins 2008 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.. Available from www.cochranehandbook.org.
45. Klijn 2001 Klijn JG, Blamey RW, Boccardo F, et al.Combined tamoxifen and luteinising hormone releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomised trials. Journal of Clinical Oncology 2001;19:343-53.
46. LHRH-Agonists 2007 LHRH-Agonists in early Breast Cancer Overview Group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-23.
47. Liddle 1996 Liddle J, Irwig L. Method for evaluating research and guideline evidence. Sydney: NSW Health Department, 1996.
48. Pagani 1998 Pagani O, O'Neil A, Castiglione M, et al.Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. European Journal of Cancer 1998;34:632-40.
49. Parmar 1998 Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival end-points. Statistics in Medicine 1998;17:2815-34.
50. Pujol 1998 Pujol P, Daures JP, Thezenas S, et al.Changing estrogen and progesterone receptor patterns in breast cancer carcinoma during the menstrual cycle and menopause. Cancer 1998;83:698-705.
51. SCTBG and ICRF 1993 Scottish Cancer Trials Breast Group (SCTBG) and ICRF Breast Unit Guys Hospital London. Adjuvant ovarian ablation versus CMF in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet 1993;341:1293-99.
52. Taylor 1998 Taylor CW, Green S, Dalton WS, et al.Multicentre randomised clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study. Journal of Clinical Oncology 1998;16:994-9.
53. Walshe 2006 Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 2006;24:5769-79.
54. Williams 2006 Williams C, Brunskill S, Altman D, et al.Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technology Assessment 2006;10(34):1-204.
55. Yusuf 1985 Yusuf S, Peto R, Lewis J, et al.Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in cardiovascular disease 1985;5:335-71.
56. Sharma 2005 Sharma R, Beith J, Hamilton A. Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer. The Breast 2005;14:181-91.